However, the validation of differentially methylated gene GAB2 in liver and adipose tissue in NASH mice may be a better substitute for replication in another population because epigenetic modifications are rather tissue specific, and furthermore verified the modification of DNA methylation of GAB2 may also be a target for the treatment of NASH, not only NAFLD. The gene discussed is GAB2; the disease is metabolic dysfunction-associated steatohepatitis.